EWM
VRTX icon

Elmwood Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Elmwood Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$0 Hold
1
– – ﹤0.01% 275
2020
Q2 		$0 Buy
+1
New +$271 ﹤0.01% 352

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Elmwood Wealth Management's VRTX Position: Q3 2020 in Review

Elmwood Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2020 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #275.

Elmwood Wealth Management first reported a position in VRTX in Q2 2020 and has held it in 2 quarters since. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Elmwood Wealth Management held 1 share of Vertex Pharmaceuticals worth $0 as of Q3 2020.
  • Elmwood Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q3 2020.
  • Vertex Pharmaceuticals made up ﹤0.01% of Elmwood Wealth Management's portfolio in Q3 2020, its #275 holding.
  • Elmwood Wealth Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Elmwood Wealth Management's 13F filing for Q3 2020, filed 12 Nov 2020.